ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020
This report can be delivered to the clients within 72 - 96 Hours
DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Overview
ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it's a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.
Discovered in 2007, “ALK-positive” refers to the rearrangement of the EML4 gene and the ALK (anaplastic lymphoma kinase) gene in DNA, resulting in a fusion oncogene EML4-ALK. An oncogene is a gene that is a mutated and may cause cancer cells.
Symptoms
Symptoms of lung cancer that are in the chest:
Anaplastic Lymphocyte Kinase is currently diagnosed by genetic testing, known as molecular testing, of a sample. Most doctors use a test called FISH (fluorescence in situ hybridization). In the United States, FISH, IHC, and NGS are approved companion diagnostic tests to identify Anaplastic Lymphocyte Kinase -positive NSCLC. In Europe, IHC is widely used to detect ALK. To obtain a sample, it is necessary to undergo a biopsy, typically through a needle biopsy or a small surgical procedure. We recommend going to an expert for this procedure, as it can be a challenging procedure.
Treatment
Crizotinib has become a reference treatment for Anaplastic Lymphocyte Kinase + NSCLC patients, and a promising treatment for tumours harbouring MET amplification and ROS1 aberrations. Unfortunately, many patients develop acquired resistance during the first year of treatment and its efficacy is limited in CNS disease. Strategies are urgently needed to overcome inherent and acquired resistance to ALK inhibition.
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the ALK-positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic Lymphocyte Kinase -positive Non-Small Cell Lung Cancer Emerging Drugs
Further product details are provided in the report……..
ALK-positive Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ALK-positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
ALK-positive Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK-positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK-positive Non-Small Cell Lung Cancer drugs.
Report Highlights
ALK-positive Non-Small Cell Lung Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Overview
ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it's a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.
Discovered in 2007, “ALK-positive” refers to the rearrangement of the EML4 gene and the ALK (anaplastic lymphoma kinase) gene in DNA, resulting in a fusion oncogene EML4-ALK. An oncogene is a gene that is a mutated and may cause cancer cells.
Symptoms
Symptoms of lung cancer that are in the chest:
- Coughing, especially if it persists or becomes intense
- Pain in the chest, shoulder, or back unrelated to pain from coughing
- A change in color or volume of sputum
- Shortness of breath
- Changes in the voice or being hoarse
- Harsh sounds with each breath (stridor)
- Recurrent lung problems, such as bronchitis or pneumonia
- Coughing up phlegm or mucus, especially if it is tinged with blood
- Coughing up blood
Anaplastic Lymphocyte Kinase is currently diagnosed by genetic testing, known as molecular testing, of a sample. Most doctors use a test called FISH (fluorescence in situ hybridization). In the United States, FISH, IHC, and NGS are approved companion diagnostic tests to identify Anaplastic Lymphocyte Kinase -positive NSCLC. In Europe, IHC is widely used to detect ALK. To obtain a sample, it is necessary to undergo a biopsy, typically through a needle biopsy or a small surgical procedure. We recommend going to an expert for this procedure, as it can be a challenging procedure.
Treatment
Crizotinib has become a reference treatment for Anaplastic Lymphocyte Kinase + NSCLC patients, and a promising treatment for tumours harbouring MET amplification and ROS1 aberrations. Unfortunately, many patients develop acquired resistance during the first year of treatment and its efficacy is limited in CNS disease. Strategies are urgently needed to overcome inherent and acquired resistance to ALK inhibition.
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the ALK-positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic Lymphocyte Kinase -positive Non-Small Cell Lung Cancer Emerging Drugs
- Ensartinib: Betta Pharmaceuticals/Xcovery
- TQ-B3139 - Chia Tai Tianqing Pharmaceutical Group
Further product details are provided in the report……..
ALK-positive Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different ALK-positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in ALK-positive Non-Small Cell Lung Cancer
Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intramuscular
- Intratumoral
- Intravenous
- Molecule Type
- Gene therapies
- Bispecific antibodies
- Immunotherapies
- Monoclonal antibodies
- Small molecules
- Product Type
ALK-positive Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK-positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK-positive Non-Small Cell Lung Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ALK-positive Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ALK-positive Non-Small Cell Lung Cancer.
- August 2020: Ensartinib Improves Progression-Free Survival in Patients with ALK-Positive NSCLC
ALK-positive Non-Small Cell Lung Cancer Report Insights
- ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing ALK-positive Non-Small Cell Lung Cancer drugs?
- How many ALK-positive Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ALK-positive Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ALK-positive Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ALK-positive Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Novartis
- AstraZeneca
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Ariad Pharmaceutica
- Takeda
- Chia Tai Tianqing Pharmaceutical Group
- Akeso
- Ensartinib
- TQ B3139
- WX-0593
- M7824
Introduction
Executive Summary
ALK-positive Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ALK-positive Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ensartinib: Betta Pharmaceuticals/Xcovery
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
PLB1003: Beijing Pearl Biotechnology Limited Liability Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ALK-positive Non-Small Cell Lung Cancer Key Companies
ALK-positive Non-Small Cell Lung Cancer Key Products
ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
ALK-positive Non-Small Cell Lung Cancer Analyst Views
ALK-positive Non-Small Cell Lung Cancer Key Companies
Appendix
Executive Summary
ALK-positive Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
ALK-positive Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ensartinib: Betta Pharmaceuticals/Xcovery
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
PLB1003: Beijing Pearl Biotechnology Limited Liability Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ALK-positive Non-Small Cell Lung Cancer Key Companies
ALK-positive Non-Small Cell Lung Cancer Key Products
ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
ALK-positive Non-Small Cell Lung Cancer Analyst Views
ALK-positive Non-Small Cell Lung Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products